

For Patients and Caregivers



SUCCEED

**Sarcoma Multi-Center Clinical Evaluation
of the Efficacy of Deforolimus**

**Important Information
for People Diagnosed with Metastatic Sarcoma
About an International Phase 3 Clinical Trial
Currently Enrolling Patients**

SUCCEED is one of the largest research trials ever conducted in patients with metastatic soft-tissue and bone sarcomas (cancer of the connective tissue or bone that has spread to other parts of the body).



**Sarcoma Multi-Center Clinical Evaluation
of the Efficacy of Deforolimus**

The SUCCEED clinical trial could change the way patients with metastatic sarcoma are treated. Patients who are currently receiving chemotherapy for the treatment of their sarcoma may wish to discuss the SUCCEED trial with their doctors to see if it may be right for them. To be a part of this trial, patients must have achieved a favorable response or have stable disease following a minimum of 4 cycles of cytotoxic chemotherapy.

Approximately 650 patients will be enrolled in the trial at approximately 125 sites worldwide.

What is a clinical trial?

A clinical trial is a type of research that tests how well new medical approaches work in people. These trials test new ways of screening, preventing, diagnosing, or treating a disease.

Why should I participate in a clinical trial?

The reasons for participating in a clinical trial include:

- Participants have access to new treatments that often aren't available otherwise
- The treatment being studied may be more effective than the standard treatment
- Participants receive regular and attentive medical care from a research team that includes doctors and other healthcare professionals
- Results of the trial may help other patients in the future

What is deforolimus?

Deforolimus is a new kind of drug; it is not a chemotherapy. In non-clinical studies, deforolimus has been shown to block a “master switch” in cancer cells. By blocking this “switch,” deforolimus causes a starvation-like effect in cancer cells, which interferes with their ability to grow, divide, and conduct processes they need to stay alive. It is designed to interfere with the formation of the blood vessels that cancer cells need in order to stay alive and continue to grow.

Who is sponsoring the trial?

The SUCCEED trial is sponsored by ARIAD Pharmaceuticals, Inc. ARIAD is a company that is focusing on the discovery and development of breakthrough medicines to treat cancer. ARIAD and Merck & Co., Inc. have a global collaboration to jointly develop and commercialize deforolimus for treatment of cancer.



**Sarcoma Multi-Center Clinical Evaluation
of the Efficacy of Deforolimus**

Why is the SUCCEED trial being conducted?

In earlier studies, deforolimus showed activity against tumors in many types of cancers, including sarcomas. The purpose of SUCCEED is to determine if deforolimus will significantly increase the time interval that patients' tumors do not progress.

Participation in this trial is completely voluntary. Patients who wish to participate or have questions after reading this brochure should speak to their doctors.

What are the objectives of the trial?

The first objective of the trial is to measure how long deforolimus can continue to maintain patients' favorable outcome after chemotherapy.

The trial will also measure overall survival with deforolimus, how well abnormal tissue responds to deforolimus, improvement in symptoms with deforolimus, and the safety and tolerability of deforolimus.

What criteria must a patient meet to be considered for this trial?

In addition to having a confirmed diagnosis of metastatic soft-tissue or bone sarcoma, a patient must meet certain other requirements for participation in the trial. Patients must have achieved a favorable response or have stable disease following a minimum of 4 cycles of cytotoxic chemotherapy. In addition, a patient's disease status must be confirmed by a review of 2 of their most recent CT or MRI scans.

Other requirements include factors such as age, response to previous treatment, and how recently previous treatment was received. Additional criteria are required and a doctor can discuss this further.

What side effects might a patient experience with deforolimus?

Information on side effects is available from a participating doctor. Briefly, patients experience different kinds and degrees of side effects from medical treatments. Side effects most commonly experienced with deforolimus may include mouth sores, rash, tiredness, higher than normal levels of certain fats in the blood, anemia, and nausea. In previous clinical trials, most side effects were mild to moderate in severity, manageable, and reversible. These are not all the side effects associated with deforolimus; a doctor can further explain the potential side effects of deforolimus.

How long will patients receive the trial treatment?

Patients will go through an initial 3-week screening process to determine if they are eligible to participate in the trial. If they meet the trial's requirements, they will participate in the trial for a period of time based on their individual response to the trial treatment. Each patient's doctor will determine how long he or she will receive treatment.



**Sarcoma Multi-Center Clinical Evaluation
of the Efficacy of Deforolimus**

Where can I find more information?

For more about the trial or to find a trial site nearby:

- Visit the trial Web site at www.succeedtrial.com
- Call the US toll-free number **1-877-621-2302**, or the international number **1-617-621-2302**
- Email us at ClinicalTrials@ARIAD.com

For more about this and other clinical trials in sarcoma, visit:

- www.ClinicalTrials.gov
- www.cancer.gov/cancertopics/factsheet/Information/clinical-trials

For more about sarcoma and to find support services for patients and their families, visit:

- Cancer Care® (www.cancercares.org)
- Liddy Shriver Sarcoma Initiative (www.liddyshriversarcomainitiative.org)
- National Cancer Institute (www.cancer.gov)
- Sarcoma Alliance (www.sarcomaalliance.org)
- Sarcoma Foundation of America (www.curesarcoma.org)

Patients interested in participating in the SUCCEED trial can also speak to their doctors.



© ARIAD Pharmaceuticals, Inc. 07SUC002 303449 1/08

